HBV inhibitor and its use
The present invention provides anti-HBV compounds, pharmaceutically acceptable compounds or stereoisomers thereof, and preparation methods and uses for treating, eradicating or inhibiting HBV infection or for alleviating liver injury caused by HBV infection, and so on.
1. A compound, pharmaceutically acceptable salt or stereoisomer thereof, the compound is selected from:
2. A pharmaceutical composition, which comprises the compound, pharmaceutically acceptable salt or stereoisomer thereof of claim 1 , and pharmaceutically acceptable auxiliary material.
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable auxiliary material is at least one of excipient, diluent, disintegrant, glidant and lubricant.
4. The pharmaceutical composition of claim 2 , which further comprises one or more antiviral agents.
5. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable auxiliary material includes dicalcium phosphate, cellulose, compressible sugar, dicalcium phosphate dehydrate, lactose mannitol, microcrystalline cellulose, starch and/or tricalcium phosphate.
6. The pharmaceutical composition of claim 4 , wherein the antiviral agent is at least one of hepatitis B virus (HBV) polymerase inhibitor, interferon, virus entry inhibitor, virus maturation inhibitor, assembly regulator, reverse transcriptase inhibitor, and TLR-agonist.
7. The pharmaceutical composition of claim 6 , wherein the reverse transcriptase inhibitor is at least one of Entecavir, Tenofovir, HepDirect-Tenofovir, Entricitabine, Adefovir, HepDirect-Adefovir (Pradefovir), Acyclovir, Ganciclovir, GS-7340 (TAF), Bestfovir, Birinapant (HY-16591), Ribavirin and Efavirenz.
8. The pharmaceutical composition of claim 7 , wherein the reverse transcriptase inhibitor is Tenofovir.
9. A compound, pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is selected from:
Com-
pound
No.
Structural Formula
62
52
53
54
55
56
57
58
59
60
77
78
10. A method for treating, eradicating, reducing or inhibiting HBV infection or for alleviating liver injury caused by HBV infection, which comprises administering to a patient in need thereof an effective dosage of the compound pharmaceutically acceptable salt or stereoisomer thereof of claim 1 .